Design of KYSA-6, a Phase 2, Open-Label, Multicenter Study of KYV-101, a Novel Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Generalized Myasthenia Gravis

被引：0
|
作者：
Haghikia, Aiden [1 ]
Borie, Dominic [2 ]
Chung, James [2 ]
Gold, Ralf [3 ]
机构：
[1] Otto von Guericke Univ, Fac Med, Dept Neurol, Magdeburg, Germany
[2] Kyverna Therapeut Inc, Emeryville, CA USA
[3] Ruhr Univ Bochum, Dept Neurol, Bochum, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1628/1868
引用
收藏
页码：1031 / 1032
页数：2
相关论文
共 50 条
  • [21] Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist
    Jacobson, Caron A.
    Farooq, Umar
    Ghobadi, Armin
    ONCOLOGIST, 2020, 25 (01): : E138 - E146
  • [22] Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial.
    Xiao, Lei
    Huang, He
    Huang, Xiaojun
    Ke, Xiaoyan
    Hu, Yu
    Li, Junmin
    Zhang, Qing
    Hu, Yongxian
    Jiang, Qian
    Hu, Jiang
    Jing, Hongmei
    Zhang, Xiaohong
    Wu, Zhao
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
    Zhang, Yunlin
    Patel, Ruchi P.
    Kim, Ki Hyun
    Cho, Hyungwoo
    Cho, Jae-Cheol
    Jeong, Seong Hyun
    Oh, Sung Yong
    Choi, Yoon Seok
    Kim, Sung-Hyun
    Lee, Ji Hyun
    Angelos, Mathew G.
    Guruprasad, Puneeth
    Cohen, Ivan J.
    Ugwuanyi, Ositadimma
    Lee, Yong Gu
    Pajarillo, Raymone
    Cho, Jong Hyun
    Carturan, Alberto
    Paruzzo, Luca
    Ghilardi, Guido
    Kim, Soohwan
    Kim, Sung Min
    Lee, Hyun Jong
    Park, Ji Ho
    Cui, Lei Guang
    Lee, Tae Bum
    Hwang, Insik
    Lee, Youngha
    Lee, Yong-Jun
    Porazzi, Patrizia
    Liu, Dongfang
    Lee, Yoon
    Kim, Jong Hoon
    Lee, Jong Seo
    Yoon, Dok Hyun
    Chung, Junho
    Ruella, Marco
    BLOOD, 2023, 142
  • [24] Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
    Granit, Volkan
    Benatar, Michael
    Kurtoglu, Metin
    Miljkovic, Milos D.
    Chahin, Nizar
    Sahagian, Gregory
    Feinberg, Marc H.
    Slansky, Adam
    Vu, Tuan
    Jewell, Christopher M.
    Singer, Michael S.
    Kalayoglu, Murat, V
    Howard Jr, James F.
    Mozaffar, Tahseen
    LANCET NEUROLOGY, 2023, 22 (07): : 578 - 590
  • [25] Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma
    Kim, Ki Hyun
    Yoon, Dok Hyun
    Jo, Jae-Cheol
    Jeong, Seong Hyun
    Oh, Sung Yong
    Cho, Hyungwoo
    Choi, Yoon Seok
    Kim, Sung-Hyun
    Lee, Ji Hyun
    Cui, LeiGuang
    Lee, Tae-Bum
    Hwang, In-Sik
    Lee, Young-Ha
    Lee, Yong-Jun
    Lee, Yoon
    Kim, Jong-Hoon
    Lee, Jong-Seo
    Chung, Junho
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).
    Nastoupil, Loretta J.
    Dahiya, Saurabh
    Miklos, David Bernard
    Reagan, Patrick Michael
    Ulrickson, Matthew
    Jung, A. Scott
    Kloos, Ioana
    Dong, Jinghui
    Chou, Justin
    Murakami, Jodi
    Rodriguez, Katherine
    Nahas, Myrna
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view
    Thielen, Frederick W.
    van Dongen-Leunis, Annemieke
    Arons, Alexander M. M.
    Ladestein, Judith R.
    Hoogerbrugge, Peter M.
    Uyl-de Groot, Carin A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (02) : 203 - 215
  • [28] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study
    Wang, Michael
    Munoz, Javier
    Goy, Andre
    Locke, Frederick L.
    Jacobson, Caron A.
    Hill, Brian T.
    Timmerman, John M.
    Holmes, Houston
    Jaglowski, Samantha
    Flinn, Ian W.
    McSweeney, Peter A.
    Miklos, David B.
    Pagel, John M.
    Kersten, Marie Jose
    Peng, Weimin
    Zheng, Lianqing
    Rossi, John M.
    Jain, Rajul K.
    Rao, Arati V.
    Reagan, Patrick M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S1 - S1
  • [29] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study
    Wang, Michael L.
    Munoz, Javier
    Goy, Andre
    Locke, Frederick L.
    Jacobson, Caron A.
    Hill, Brian T.
    Timmerman, John M.
    Holmes, Houston
    Jaglowski, Samantha
    Flinn, Ian W.
    McSweeney, Peter A.
    Miklos, David B.
    Pagel, John M.
    Kersten, Marie Jose
    Peng, Weimin
    Zheng, Lianqing
    Rossi, John M.
    Jain, Rajul K.
    Rao, Arati V.
    Reagan, Patrick M.
    BLOOD, 2019, 134
  • [30] Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL
    Zhou, Lili
    Huang, Jiaqi
    Zhu, Shigui
    Yao, Xin
    Ye, Shiguang
    Zhu, Judy
    Zheng, Chengxiao
    Chen, Shiyi
    Li, Yanfeng
    Lan, Liping
    Chen, Shicheng
    Guo, Lin
    Zhang, Qingsong
    Zheng, Jiangqin
    Wang, Rirfei
    Hong, Yi
    Ren, Jiaqiang
    Zhang, Li
    Zhang, Wenjun
    Tang, Xiaochen
    Wang, Junbang
    Liu, Jie
    Humphries, Michael
    Li, Ping
    Yao, Yihong
    Liang, Aibin
    BLOOD, 2020, 136
12345